Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout
Sanofi halts development of a key eczema treatment derived from its Kymab acquisition following a recent pipeline review.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Sanofi is discontinuing the development of the OX40L antibody amlitelimab, originally acquired through its purchase of Kymab. The decision follows a broad review of the pharmaceutical company's drug pipeline conducted under the leadership of its new CEO.
Coverage from BioSpace, Endpoints News, FirstWord Pharma, WSJ, and Fierce Biotech emphasizes that this shift marks a significant change for the Kymab-related assets. Reports vary on the valuation of the initial buyout, citing figures between $1.1 billion and $1.4 billion.
Future updates will depend on further disclosures regarding the impact of the pipeline review on Sanofi’s remaining drug candidates. Coverage does not yet specify the long-term strategic adjustments expected under the company's new management.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.
Quick answers
What drug is being discontinued?
Sanofi is shelving amlitelimab, an OX40L antibody intended for atopic dermatitis.
Why is the project being canceled?
The cancellation follows a pipeline review conducted under Sanofi's new CEO.
What was the cost of the Kymab acquisition?
Reports vary, with sources citing both $1.1 billion and $1.4 billion.
Coverage (5)
- Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped BioSpace · 1d ago
- Sanofi nixes Kymab-originated OX40L antibody in eczema Endpoints News · 1d ago
- Sanofi shelves amlitelimab in atopic dermatitis after pipeline review FirstWord Pharma · 1d ago
- Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO WSJ · 1d ago
- Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout Fierce Biotech · 1d ago
Topics
Related trends
Sanofi snags FDA thumbs up for Sarclisa as 1st cancer drug delivered by on-body injector
The FDA has granted approval for Sanofi’s Sarclisa, marking the first time a cancer medication has been cleared for delivery via an on-body injector.
Sanofi under antitrust probe as European Commission kicks off formal proceedings
EU antitrust probe targets Sanofi’s flu vaccine campaign—what’s the scope and next move?
Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers
Gene therapy pioneer Sangamo Therapeutics files for bankruptcy, with Lilly and Astellas racing to acquire its assets
Teplizumab drug to delay type 1 diabetes to be rolled out on the NHS
NHS becomes first in Europe to fund drug that can delay type 1 diabetes by years